Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) - Full Text View

Sponsor:	University of California, San Diego
Information provided by:	University of California, San Diego
ClinicalTrials.gov Identifier:	NCT00706173

Purpose

Developing novel and effective pharmacologic interventions for this post-traumatic stress disorder is important. The investigators propose to replicate findings of an earlier published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do so in a more meaningful way, the investigators will conduct a larger but similar randomized double-blind placebo-controlled, cross-over design treatment study examining the use of low dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.

The investigators hypothesize that, as described by Aerni et al. (2004), administration of daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for re-experiencing types (e.g., flashbacks, nightmares)of symptoms. The investigators also hope to examine potential predictors and moderators of treatment response based on subjects' clinical characteristics, as well as serum cortisol and ACTH levels.

Condition	Intervention	Phase
Post-Traumatic Stress Disorder	Drug: Hydrocortisone Drug: Placebo	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Efficacy Study
Official Title:	A Randomized Double-blind Placebo-controlled Cross-over Trial of Hydrocortisone for Post-traumatic Stress Disorder

Resource links provided by NLM:

MedlinePlus related topics: Post-Traumatic Stress Disorder

Drug Information available for: Hydrocortisone acetate Hydrocortisone Proctofoam-HC Hydrocortisone hemisuccinate Hydrocortamate Hydrocortisone 21-sodium succinate Hydrocortisone cypionate Cortisol succinate Cortisol 21-phosphate

U.S. FDA Resources

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:

Clinician Administered PTSD Scale (CAPS) [ Time Frame: Week 0,2,4,6,8,10 ] [ Designated as safety issue: No ]
Clinical Global Impressions - Improvement (CGI-I) [ Time Frame: Week 0,2,4,6,8,10 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Sheehan Disability Inventory (SDI) [ Time Frame: Week 0,4,6,10 ] [ Designated as safety issue: No ]
Brief Symptom Inventory - 18 item (BSI-18) [ Time Frame: Week 0,2,4,6,8,10 ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	August 2009
Estimated Study Completion Date:	September 2011
Estimated Primary Completion Date:	September 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Hydrocortisone: Experimental	Drug: Hydrocortisone Hydrocortisone 10-20 mg PO daily for 4 weeks.
Placebo: Placebo Comparator	Drug: Placebo Placebo "10-20 mg" PO daily for 4 weeks.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male military veterans
Between the ages of 18-65 years old
Generally good medical health with no clinically significant abnormalities on physical examination, electrocardiogram, or laboratory findings
Ability to provide informed consent and comply with requirements of study protocol
No specific contraindications to hydrocortisone
Clinically predominant DSM-IV diagnosis of PTSD
Score of ≥ 40 on Clinician Administered PTSD Scale [CAPS]

Exclusion Criteria:

History of moderate to severe traumatic brain injury, seizure or organic mental illness
Lifetime history of schizophrenia, bipolar disorder, other psychotic disorder, or depression with a score of ≥ 16 on the 17-item Hamilton Depression Rating Scale (Hamilton, 1960), active suicidal ideation
Unstable medical illness
Subjects undergoing any formal psychotherapy within 3 months of enrollment
Subjects that meet criteria for substance dependence during the last 6 months
History of adverse reaction to corticosteroids.
Concurrent use of other psychotropic medication (e.g. benzodiazepines, antipsychotics)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00706173

Contacts

Contact: Holly Ramsawh, PhD	858-534-6445	hramsawh@ucsd.edu
Contact: Murray B Stein, MD, MPH	858-534-6400	mstein@ucsd.edu

Locations

United States, California
University of California, San Diego	Recruiting
La Jolla, California, United States, 92037
Contact: Holly Ramsawh, PhD 858-534-6445 hramsawh@ucsd.edu
Principal Investigator: Murray B Stein, MD, MPH

Sponsors and Collaborators

University of California, San Diego

Investigators

Principal Investigator:

Murray B Stein, MD, MPH

University of California, San Diego

More Information

Additional Information:

UCSD Anxiety Disorders Research Program This link exits the ClinicalTrials.gov site

Publications:

Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, Nitsch RM, Schnyder U, de Quervain DJ. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry. 2004 Aug;161(8):1488-90.

Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhäusler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry. 2001 Dec 15;50(12):978-85.

Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A, Rothenhäusler HB, Krauseneck T, Nollert G, Kapfhammer HP. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry. 2004 Mar 15;55(6):627-33.

Olff M, Güzelcan Y, de Vries GJ, Assies J, Gersons BP. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology. 2006 Nov;31(10):1220-30. Epub 2006 Nov 1.

Responsible Party:	University of California, San Diego ( Murray B. Stein )
Study ID Numbers:	071982
Study First Received:	June 25, 2008
Last Updated:	August 19, 2009
ClinicalTrials.gov Identifier:	NCT00706173 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, San Diego:

Post-traumatic stress disorder
PTSD
Cortisol
hydrocortisone
pharmacological treatment

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Disease
Hydrocortisone
Cortisol succinate
Stress
Stress Disorders, Traumatic
Pharmacologic Actions

Pathologic Processes
Anxiety Disorders
Mental Disorders
Therapeutic Uses
Stress Disorders, Post-Traumatic
Hydrocortisone acetate

ClinicalTrials.gov processed this record on November 11, 2009